---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-007586"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:13:52.690830+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcutis licenses ZORYVE to Sato for Japan; $25M upfront, up to $65M milestones

## Summary
- Upfront payment of $25M; up to $10M in regulatory milestones and $30M in sales milestones.
- Royalties of low double-digit to mid-teen double-digit percentage on net sales in Japan.
- Sato exclusively develops and commercializes ZORYVE cream and foam for dermatological indications in Japan.
- Arcutis retains approval and oversight rights over development and commercialization activities.

## SEC filing metadata
- accession: 0001628280-24-007586
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000162828024007586/0001628280-24-007586-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000162828024007586/arqt-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-007586
- JSON: https://secwatch.observer/filing/0001628280-24-007586.json
- Plain text: https://secwatch.observer/filing/0001628280-24-007586.txt

## Key facts
- Material Agreements
  Arcutis Biotherapeutics, Inc. entered into License Agreement with Sato Pharmaceutical Co., Ltd. valued at an upfront payment of $25 million (effective 2024-02-27).
  - Action: entry
  - Agreement: license
  - Counterparty: Sato Pharmaceutical Co., Ltd.
  - Value: an upfront payment of $25 million
  - Effective: 2024-02-27
  source text: On February 27, 2024, Arcutis Biotherapeutics, Inc. (“Arcutis” or the “Company”) entered into a License Agreement (the “License Agreement”) with Sato Pharmaceutical Co., Ltd. (“Sato”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000162828024007586/0001628280-24-007586-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.